A prospective, open-label, multi-cohort study assessing the Changes in immune function and prognosis in advanced perihilar cholangiocarcinoma patients treated with immunotherapy combined with different topical therapies
Latest Information Update: 09 Oct 2020
Price :
$35 *
At a glance
- Drugs Camrelizumab (Primary) ; Capecitabine (Primary) ; Fluorouracil (Primary) ; Oxaliplatin (Primary)
- Indications Cholangiocarcinoma
- Focus Adverse reactions; Therapeutic Use
- 09 Oct 2020 New trial record
- 21 Sep 2020 Trial design presented at the 45th European Society for Medical Oncology Congress